Kidney Cancer Trial, Recruiting NCT06262516 Sponsor: Case Comprehensive Cancer Center Condition: Kidney Cancer
Back to Kidney Cancer

Kidney Cancer Trial, Recruiting

NCT06262516
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with a cancer in the upper urinary tract (the lining of the kidney or ureter), confirmed by a tissue sample (biopsy)
  • Your surgeon has planned for you to have surgery to remove the affected kidney and ureter (called a nephroureterectomy)
  • Your cancer has not spread beyond a certain stage, and you have had full staging scans (CT or MRI) of your chest, abdomen, and pelvis before surgery
  • You do not have invasive bladder cancer at the same time as your upper urinary tract cancer
  • You are able to understand the study information and are willing to sign a consent form

Who may not be able to join:

  • Your lymph nodes appear enlarged in a way that suggests the cancer may have spread to them
  • Your cancer has spread to other parts of the body (distant metastases)
  • You also have invasive bladder cancer at the same time
  • You are in poor general health or have another life-threatening illness
  • You have a psychiatric condition that makes it difficult to understand or agree to take part in the study
  • You are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mohamed Eltemamy, MD, Cleveland Clinic, Glickman Urological and Kidney Institute, Case Comprehensive Cancer Center

Phone: 216-444-5888

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
17 May 2024
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Recurrence-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov